<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="28/06/2006" creator="Noriko Katsu" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10364191"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>10364191</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Potent and stable attenuation of <term sem="Virus" id="T1" lex="live-HIV-1">live-HIV-1</term> by gain of a <term sem="Protein_family_or_group" id="T2" lex="proteolysis-resistant_inhibitor">proteolysis-resistant inhibitor</term> of <term sem="Protein_complex" id="T3" lex="NF-kappaB">NF-kappaB</term> (<term sem="Protein_molecule" id="T4" lex="IkappaB-alphaS32/36A">IkappaB-alphaS32/36A</term>) and the implications for <term sem="Other" id="T5" lex="vaccine_development">vaccine development</term>.</sentence>
<event id="E1">
<type class="Negative_regulation" />
<theme idref="T1" />
<cause idref="T4" />
<clue>Potent and stable <clueType>attenuation</clueType> <linkTheme>of</linkTheme> live-HIV-1 <linkCause>by gain of</linkCause> a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development.</clue>
</event>
<event id="E2">
<type class="Negative_regulation" />
<theme idref="T3" />
<cause idref="T4" />
<clue>Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant <clueType>inhibitor</clueType> <linkTheme>of</linkTheme> NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development.</clue>
</event>
<event assertion="non-exist" id="E3">
<type class="Protein_catabolism" />
<theme idref="T4" />
<clue>Potent and stable attenuation of live-HIV-1 by gain of a <clueType>proteolysis</clueType>-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term sem="Virus" id="T6" lex="live-attenuated_human_immunodeficiency_virus">Live-attenuated human immunodeficiency viruses</term> (<term sem="Virus" id="T7" lex="HIV">HIVs</term>) are candidates for <term sem="Other" id="T8" lex="Acquired_Immunodeficiency_Syndrome_(AIDS)_vaccine">Acquired Immunodeficiency Syndrome (AIDS) vaccine</term>.</sentence>
<event id="E4">
<type class="Regulation" />
<theme idref="T7" />
<clue>Live-<clueType>attenuated</clueType> human immunodeficiency viruses (HIVs) are candidates for Acquired Immunodeficiency Syndrome (AIDS) vaccine.</clue>
</event>
<sentence id="S3">Based on the <term sem="Virus" id="T9" lex="simian_immunodeficiency_virus_(SIV)_model">simian immunodeficiency virus (SIV) model</term> for <term sem="Other" id="T10" lex="AIDS">AIDS</term>, <term sem="Other" id="T11" lex="loss-of-function">loss-of-function</term> (e.g. deletion of accessory genes such as <term sem="DNA_domain_or_region" id="T12" lex="nef">nef</term>) has been forwarded as a primary approach for creating <term sem="Virus" id="A20">enfeebled, but replication-competent, <term sem="Virus" id="T13" lex="HIV-1/SIV">HIV-1/SIV</term></term>.</sentence>
<event id="E5">
<type class="Mutagenesis" />
<theme idref="T12" />
<clue>Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. <clueType>deletion</clueType> <linkTheme>of</linkTheme> <corefTheme>accessory genes</corefTheme> such as nef) has been forwarded as a primary approach for creating enfeebled, but replication-competent, HIV-1/SIV.</clue>
<comment>ARTIFICIAL</comment></event>
<event uncertainty="doubtful" id="E23">
<type class="Positive_regulation" />
<theme idref="A20" />
<cause idref="E5" />
<clue>Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for <clueType>creating</clueType> enfeebled, but replication-competent, HIV-1/SIV.</clue>
<comment>TPS: A20</comment></event>
<event id="E21">
<type class="Negative_regulation" />
<theme idref="T13" />
<clue>Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for creating <clueType>enfeebled</clueType>, but replication-competent, HIV-1/SIV.</clue>
</event>
<event id="E22">
<type class="Viral_life_cycle" />
<theme idref="T13" />
<clue>Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for creating enfeebled, but <clueType>replication</clueType>-competent, HIV-1/SIV.</clue>
</event>
<sentence id="S4">Regrettably, recent evidence suggests that <term sem="Other" id="T14" lex="loss-of-function">loss-of-function</term> alone is not always sufficient to prevent the emergence of <term sem="Virus" id="T15" lex="virulent_mutants">virulent mutants</term>.</sentence>
<event id="E6">
<type class="Negative_regulation" />
<theme idref="T15" />
<cause idref="T14" />
<clue>Regrettably, recent evidence suggests that loss-of-function alone is not always sufficient to <clueType>prevent the emergence</clueType> <linkTheme>of</linkTheme> virulent mutants.</clue>
</event>
<event assertion="non-exist" id="E15">
<type class="Negative_regulation" />
<theme idref="T15" />
<cause idref="T14" />
<clue>Regrettably, recent evidence suggests that loss-of-function alone is not always sufficient to <clueType>prevent the emergence</clueType> <linkTheme>of</linkTheme> virulent mutants.</clue>
</event>
<sentence id="S5">New strategies that attenuate via mechanisms distinct from <term sem="Other" id="T16" lex="loss-of-function">loss-of-function</term> are needed for enhancing the safety phenotype of <term sem="DNA_family_or_group" id="T17" lex="viral_genome">viral genome</term>.</sentence>
<sentence id="S6">Here, we propose <term sem="Other" id="T18" lex="gain-of-function">gain-of-function</term> to be used simultaneously with <term sem="Other" id="T19" lex="loss-of-function">loss-of-function</term> as a novel approach for attenuating <term sem="Virus" id="T20" lex="HIV-1">HIV-1</term>.</sentence>
<event uncertainty="doubtful" id="E7">
<type class="Negative_regulation" />
<theme idref="T20" />
<cause idref="T18" />
<clue>Here, we propose gain-of-function to be used simultaneously with loss-of-function as a novel approach for <clueType>attenuating</clueType> HIV-1.</clue>
</event>
<event id="E20">
<type class="Negative_regulation" />
<theme idref="T20" />
<cause idref="T19" />
<clue>Here, we propose gain-of-function to be used simultaneously with loss-of-function as a novel approach for <clueType>attenuating</clueType> HIV-1.</clue>
</event>
<sentence id="S7">We have constructed an <term sem="DNA_family_or_group" id="A1"><term sem="DNA_family_or_group" id="T21" lex="HIV-1_genome"><term sem="Virus" id="T22" lex="HIV-1">HIV-1</term> genome</term> carrying the <term sem="DNA_family_or_group" id="T23" lex="cDNA">cDNA</term></term> of a <term sem="Protein_family_or_group" id="T24" lex="proteolysis-resistant_nuclear_factor-kappaB_inhibitor">proteolysis-resistant nuclear factor-kappaB inhibitor</term> (<term sem="Protein_molecule" id="T25" lex="IkappaB-alphaS32/36A">IkappaB-alphaS32/36A</term>) in the <term sem="DNA_domain_or_region" id="T26" lex="nef_region"><term sem="DNA_domain_or_region" id="T27" lex="nef">nef</term> region</term>.</sentence>
<event assertion="non-exist" id="E9">
<type class="Protein_catabolism" />
<theme idref="T25" />
<clue>We have constructed an HIV-1 genome carrying the cDNA of a <clueType>proteolysis</clueType>-resistant nuclear factor-kappaB inhibitor (IkappaB-alphaS32/36A) in the nef region.</clue>
</event>
<event id="E8">
<type class="Negative_regulation" />
<theme idref="E9" />
<clue>We have constructed an HIV-1 genome carrying the cDNA of a proteolysis-<clueType>resistant</clueType> nuclear factor-kappaB inhibitor (IkappaB-alphaS32/36A) in the nef region.</clue>
</event>
<sentence id="S8"><term sem="Virus" id="A21"><term sem="Virus" id="T28" lex="HIV-1">HIV-1</term> expressing <term sem="Protein_molecule" id="T29" lex="IkappaB-alphaS32/36A">IkappaB-alphaS32/36A</term></term> down-regulates <term sem="Other" id="T30" lex="viral_expression">viral expression</term> and is highly attenuated in both <term sem="Cell_cultured" id="T31" lex="Jurkat_cell">Jurkat</term> and <term sem="Cell_natural" id="T32" lex="peripheral_blood_mononuclear_cell">peripheral blood mononuclear cells</term>.</sentence>
<event id="E10">
<type class="Gene_expression" />
<theme idref="T29" />
<clue>HIV-1 <clueType>expressing</clueType> IkappaB-alphaS32/36A down-regulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells.</clue>
</event>
<event id="E11">
<type class="Negative_regulation" />
<theme idref="E24" />
<cause idref="E10" />
<clue>HIV-1 expressing IkappaB-alphaS32/36A <clueType>down-regulates</clueType> viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells.</clue>
</event>
<event id="E24">
<type class="Viral_life_cycle" />
<theme idref="A21" />
<clue>HIV-1 expressing IkappaB-alphaS32/36A down-regulates <corefTheme>viral</corefTheme> <clueType>expression</clueType> and is highly attenuated in both Jurkat and peripheral blood mononuclear cells.</clue>
</event>
<event id="E12">
<type class="Negative_regulation" />
<theme idref="E10" />
<clue>HIV-1 expressing IkappaB-alphaS32/36A down-regulates viral expression and is highly <clueType>attenuated</clueType> <clueLoc>in</clueLoc> both <clueLoc>Jurkat</clueLoc> and peripheral blood mononuclear <clueLoc>cells</clueLoc>.</clue>
</event>
<event id="E25">
<type class="Negative_regulation" />
<theme idref="E10" />
<clue>HIV-1 expressing IkappaB-alphaS32/36A down-regulates viral expression and is highly <clueType>attenuated</clueType> <clueLoc>in</clueLoc> both Jurkat and <clueLoc>peripheral blood mononuclear cells</clueLoc>.</clue>
</event>
<sentence id="S9">We provide formal proof that the phenotypic and attenuating characteristics of <term sem="Protein_molecule" id="T33" lex="IkappaB-alphaS32/36A">IkappaB-alphaS32/36A</term> permit its stable maintenance in a live, replicating <term sem="Virus" id="T34" lex="HIV-1">HIV-1</term> despite 180 days of forced ex vivo passaging in <term sem="Tissue_cultured" id="T35" lex="tissue_culture">tissue culture</term>.</sentence>
<event id="E13">
<type class="Positive_regulation" />
<theme idref="T33" />
<clue>We provide formal proof that the phenotypic and attenuating characteristics of IkappaB-alphaS32/36A permit its stable <clueType>maintenance</clueType> <clueLoc>in a live, replicating HIV-1</clueLoc> despite <clueTime>180 days</clueTime> of forced ex vivo passaging in tissue culture.</clue>
</event>
<event id="E14">
<type class="Viral_life_cycle" />
<theme idref="T34" />
<clue>We provide formal proof that the phenotypic and attenuating characteristics of IkappaB-alphaS32/36A permit its stable maintenance in a live, <clueType>replicating</clueType> HIV-1 despite 180 days of forced ex vivo passaging in tissue culture.</clue>
</event>
<sentence id="S10">As compared with other <term sem="DNA_family_or_group" id="T36" lex="open-reading_frame">open-reading frames</term> embedded into <term sem="DNA_family_or_group" id="T37" lex="HIV/SIV_genome">HIV/SIV genome</term>, this degree of stability is unprecedented.</sentence>
<event id="E16">
<type class="Mutagenesis" />
<theme idref="T36" />
<theme idref="T37" />
<clue>As compared with other open-reading frames <clueType>embedded</clueType> <linkTheme>into</linkTheme> HIV/SIV genome, this degree of stability is unprecedented.</clue>
<comment>ARTIFICIAL</comment></event>
<sentence id="S11">Thus, <term sem="Protein_molecule" id="T38" lex="IkappaB-alphaS32/36A">IkappaB-alphaS32/36A</term> offers proof-of-principle that artifactually gained functions, when used to attenuate the replication of <term sem="Virus" id="T39" lex="live_HIV-1">live <term sem="Virus" id="T40" lex="HIV-1">HIV-1</term></term>, can be stable.</sentence>
<event id="E17">
<type class="Negative_regulation" />
<theme idref="E18" />
<cause idref="T38" />
<clue>Thus, IkappaB-alphaS32/36A offers proof-of-principle that artifactually gained functions, when used to <clueType>attenuate</clueType> the replication of live HIV-1, can be stable.</clue>
</event>
<event id="E18">
<type class="Viral_life_cycle" />
<theme idref="T40" />
<clue>Thus, IkappaB-alphaS32/36A offers proof-of-principle that artifactually gained functions, when used to attenuate the <clueType>replication</clueType> <linkTheme>of</linkTheme> live HIV-1, can be stable.</clue>
</event>
<sentence id="S12">These findings illustrate <term sem="Other" id="T41" lex="gain-of-function">gain-of-function</term> as a feasible strategy for developing safer <term sem="Virus" id="T42" lex="live-attenuated_HIV">live-attenuated <term sem="Virus" id="T43" lex="HIV">HIVs</term></term> to be tested as candidates for <term sem="Other" id="T44" lex="AIDS_vaccine">AIDS vaccine</term>.</sentence>
<event id="E19">
<type class="Negative_regulation" />
<theme idref="T43" />
<clue>These findings illustrate gain-of-function as a feasible strategy for developing safer live-<clueType>attenuated</clueType> HIVs to be tested as candidates for AIDS vaccine.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
